TG Therapeutics, Inc. (LON:0VGI)

Market Cap	3.66B
Revenue (ttm)	331.42M
Net Income (ttm)	44.13M
Shares Out	n/a
EPS (ttm)	0.26
PE Ratio	82.84
Forward PE	21.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,474
Average Volume	3,895
Open	37.11
Previous Close	28.07
Day's Range	37.11 - 37.11
52-Week Range	21.22 - 38.55
Beta	n/a
RSI	58.10
Earnings Date	Nov 4, 2025

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1993
• Employees: 338
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VGI

Financial Performance

In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.

Financial numbers in USD